Oncolytics Biotech Inc. Announces Issuance of 23rd U...(actual results to differ materially from...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
Date:9/4/2007
actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.
'/>"/>
| SOURCE Oncolytics Biotech Inc. Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
Breaking Biology Technology:miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3
[0] miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease[0] Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans[0] For Release: Esco Announces 2nd North American Facility in Marietta, OH [0] NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont
Other Biology Technology:Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S. 2Siemens Customers Innovate Their Clinical and Financial Workflows with Help from Soarian 2Siemens Customers Innovate Their Clinical and Financial Workflows with Help from Soarian 3Siemens Expands the SOMATOM Definition(TM) Line With World's First Adaptive CT Scanner 2Siemens Expands the SOMATOM Definition(TM) Line With World's First Adaptive CT Scanner 3Siemens Expands the SOMATOM Definition(TM) Line With World's First Adaptive CT Scanner 4Siemens Expands the SOMATOM Definition(TM) Line With World's First Adaptive CT Scanner 5
Breaking Biology News(10 mins):Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 3Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 4Roe of marine animals is best natural source of omega-3 2Experts: Disease-resistant plants enhance profits, client satisfaction 2SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies 13731 1SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies 13731 2NTU and Temasek Foundation transfer technology knowhow to Chinas quake prone regions 9723 1NTU and Temasek Foundation transfer technology knowhow to Chinas quake prone regions 9723 2NTU and Temasek Foundation transfer technology knowhow to Chinas quake prone regions 9723 3Sinovac Wins Beijing Public Health Bureaus Bid to Supply Seasonal Flu Vaccine Anflu 28R 29 to Beijing Citizens 55599 1Sinovac Wins Beijing Public Health Bureaus Bid to Supply Seasonal Flu Vaccine Anflu 28R 29 to Beijing Citizens 55599 2Sinovac Wins Beijing Public Health Bureaus Bid to Supply Seasonal Flu Vaccine Anflu 28R 29 to Beijing Citizens 55599 3
Other Biology News:Weekends slow weight loss, researchers find 2Weekends slow weight loss, researchers find 3Gift of $100 million to transform energy and environment research at Princeton 2Gift of $100 million to transform energy and environment research at Princeton 3Gift of $100 million to transform energy and environment research at Princeton 4Political participation is partially rooted in genetic inheritance 2Political participation is partially rooted in genetic inheritance 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |